List of Bioinformatics Companies in New York - 38

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections. Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development. Our approach integrates interdisciplinary ingenuity with computational tools to design new drug candidates using our proprietary SCULPT platform. Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. Fragments are incorporated into the target-specific construction of combinatorial in silico libraries, which are designed based on synthetic feasibility. Libraries consisting of thousands to millions of small molecules are iteratively built, and computationally evaluated for potency and optimal ADMET properties. The final selection is made from dozens of iterations, totaling upwards of 100 million compounds.

Achira is building atomistic foundation simulation models to power the future of drug discovery.

Aclid is a security and safety platform for synthetic biology. The company's DNA screening solution for biosecurity, export control compliance, and EH&S keeps researchers safe and protects national security.

Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.

The Genomics Core serves the Einstein scientific community by providing a broad range of services, utilizing current and emerging nucleic acid technologies. Single-cell assays, MPS, Microarrays, real-time PCR, Sanger sequencing and assay automation are available. The Core provides a number of technologies for genotyping DNA from humans or model organisms, varying from SNP (single nucleotide polymorphism) typing to targeted sequencing for variant discovery.

Ancilia is harnessing the natural power of CRISPR to develop a new class of bacterial therapies and products for a range of applications.

Basepair is a next generation bioinformatics company. Through a combination of intuitive interfaces and modern architecture we are reimagining what a commercial platform can deliver to R&D organizations. We're on a mission to make genomic data analysis & visualization more accessible to a broader range of scientists so that the promise of precision medicine can become a reality. One of the biggest challenges preventing this now arguably lies not with how the data gets generated and processed, but who is able to perform the analysis and understand what the resulting data means. Limiting this work to a select few, whether through choice or more often because of technology restrictions, especially for routine analyses, leads to reduced efficiency in R&D teams, longer times to market for assay manufacturers and increased turnaround times in clinical settings. Unlike other more traditional alternatives, our philosophy is not to ask bioinformaticians to change the way they work by having to build workflows on our platform. Instead, once they are built and ready for sharing or production settings, Basepair can significantly improve and accelerate both scaling & deployment to colleagues, collaborators and customers wherever they happen to be in the world. To do this in a way that is adapted to the dynamics of the market today, we believe a bioinformatics platform needs to: 1) Leverage the compute and storage resources in a third party cloud account without the requirement of installing inside an organization's vpc 2) Facilitate the bundling of analysis with the sale of a kit or assay through easy white labeling and tokens/coupons 3) Support ever increasing sample volumes and application areas through an extensible architecture that scales to millions of records, enables complete sample provenance and reduces cloud costs Introducing Basepair…bioinformatics reinvented.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

CD ComputaBio is a professional computational biology service company. Our service spans across different areas in computational biology, providing access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. We are committed to providing high-quality data and customer service to various industrial and academic customers.

CD Genomics is aiming at providing the research community with high quality Next Generation Sequencing, high throughput microarray services. Due to the demand for our services has being increased; CD Genomics has already updated its technology platform to mainstream NGS and microarray instruments. At present, our senior bioinformaticians have ever viewed more than ten thousands of trace files and accumulated abundant experience with our Illumina HiSeq2000/2500, Illumia Miseq, Ion Torrent PGM, PacBio RS and ABI 3730/3730XL analyzers. We continue to work hard to offer you the same dependable services to pharmaceutical and biotech companies, as well as academia and government agencies for the purpose of satisfying all your sequencing or array needs. In 2007, CD Genomics has expanded its services to molecular biology research and its development needs. We have become a service provider in sequencing, microarray analysis, library construction and genotyping. Our progress could not be achieved without our large group of client's support. Through nearly ten year's hard working and depend on our professional work team, we are proud of satisfying the needs of our clients both at home and abroad, which across more than 50 countries and districts. We always devote ourselves to providing you with the best and professional service.

Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead “pipeline-in-a-pill” AMHR2 program focused on ovarian senescence, and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies. For more information visit www.celmatix.com.

CMTx Biotech is commercializing a pipeline of proprietary, non-antibiotic, chemically-modified tetracycline (CMT) compositions and formulations for the host-modulatory treatment of diseases with high unmet needs. The company’s lead drug candidate is a clinical-stage, orally-administered small molecule (incyclinide / CMT-3 / COL-3) for the treatment of hospitalized sepsis patients at risk of septic shock, multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS), including from SARS-CoV-2 infection (COVID-19) and other infectious diseases. Our clinical-stage drug candidate has already demonstrated impressive efficacy in a number of animal models of sepsis/ARDS/MODS across multiple species (rats, mice, pigs, sheep). It has also been evaluated in over 450 patients across eleven Phase I/II clinical studies, which showed that the drug is well-tolerated. CMTx Biotech also has a pipeline of pre-clinical stage analogues for the treatment of diseases with high unmet need.

COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real-world data. By using our proprietary technology, advanced analytics and deep expertise to organize complex data, we provide a comprehensive picture of cancer that can be used to advance care and research. ‍We believe that everyone touched by cancer deserves a clear path to care. Together, we can make that vision a reality.

Creative Proteomics has gradually developed into an integrated company that provides proteomics, metabolomics, glycomics, and bioinformatics analysis services to researchers in the pharmaceutical, biotechnology, agriculture and nutrition industries, as well as academic and government organizations. With a continuing focus on quality, we are proud of satisfying the needs of our clients both at home and abroad covering more than 50 countries and districts.

Duality's breakthrough innovative technologies eliminate the conflict between data protection and business growth and innovation. The Duality Data Analytics and AI platform is built upon advanced encryption methods, hardware technologies, and machine learning techniques that protect sensitive data while in use. Duality is the only multi-PET platform with the ability to combine various technologies to meet the unique needs of sensitive data operations. These guardrails streamline and enhance the data operations critical for data-driven insights and innovations by eliminating bulky, expensive, and limiting processes like data anonymization and tokenization. Traditional data protection methods prevent organizations from truly adopting and leveraging advanced models to their benefit, resulting in restrictive policies like "no sensitive data can be used for model training." With Duality, organizations can confidently customize 3rd party models on their own data without fear of data leaks. Model providers can scale model customization knowing that their proprietary model is never exposed to the customer, preventing competitive intelligence leaks. Financial institutions can turn their manual KYC requests into self-service operations, greatly enhancing the speed and success of these expensive requirements. The benefits of data protection guardrails span from efficiency gains, to unlocking previously inaccessible data, to slashing costs on high-security infrastructure.

Embleema's software platform brings precision medicine sooner to patients by collecting and generating regulatory-grade evidence. Our platform natively unifies clinical, molecular and real-world data and is the sole one used by the FDA for its regulatory evaluation of health products involving genomic datasets. The protocols and algorithms contained in our platform are also the basis for future CDISC standards for cell and gene therapies. The FDA also uses our platform to produce regulatory grade genomic sequences for SARS-CoV-2 and other microbial pathogens (project ARGOS). In addition to the FDA, our platform powers the Lupus Landmark Study, the largest clinical study for lupus in the world, the Human Epilepsy Projects and tens of other clinical studies for pharmaceutical companies, biotechs and patient groups. More than half of the top 10 Investigational sites in the US use our platform: John Hopkins, NYU, UCSF, Yale, UPenn, Washington University in St Louis, Cornell and many others also such as Mayo Clinic, Yale, Georgetown.

Empyrean is harnessing the power of genetic engineering to transform how we treat severe neuropsychiatric and neurologic diseases.

EvolutionaryScale is a biotech startup focused on AI research in the field of biology. The company has developed a database of over 2 billion protein sequences to train its AI model, offering technology that can provide insights into biological processes. EvolutionaryScale has raised significant funding, including a $142 million seed round, and is known for its ESM3 Generative AI Model for biology.

Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.

Gencove creates high-volume, cost-sensitive sequencing software-as-a-service to help academic, agriculture, biotech, diagnostic, and pharmaceutical companies get all the genomic information they need to make life-saving discoveries.

Inductive Bio is a biotechnology company based in San Francisco, California, founded in 2022. The company specializes in using advanced machine learning and data analytics to enhance the compound optimization process in small molecule drug discovery. With a seed funding of $4.3 million, Inductive Bio aims to address challenges in Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) during drug development. The company's core offering is a proprietary dataset combined with sophisticated machine learning models. This platform enables scientists to efficiently optimize initial compounds into viable leads and development candidates, providing real-time predictions and insights throughout the drug design process. Inductive Bio collaborates with pharmaceutical companies, biotech firms, and research institutions, including a partnership with Nested Therapeutics focused on precision medicine for challenging cancers.

INNOVIMMUNE is a specialty Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule NME immunomodulatory drugs for the treatment of Autoimmune, Inflammatory and Oncologic Diseases. Follow us on Twitter: @Innovimmune

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.

LifeNome's AI algorithm looks at 9000+ genetic variations holistically (rather than other companies that look at single gene associations)to assess your overall predispositions for nutrition, fitness, skin care and many more wellness traits.​

Manas AI is a full-stack, AI-driven drug discovery company. By harnessing the power of proprietary AI models and leveraging extensive computational infrastructure, the company aims to dramatically reduce drug discovery timelines. Co-founded by Dr. Siddhartha Mukherjee and Reid Hoffman, and a world-class interdisciplinary team that spans AI, computational chemistry, biology, and clinical research, Manas AI is on a mission to bring life-saving treatments to patients faster than ever before.

Massive Bio collects and curates the latest scientific knowledge in genomics of cancer, connects with clinical information incorporate all new discoveries in treatment plans.

Nebula Genomics is a genomics company that offers genome understanding, disease cure assistance, and data ownership through blockchain technology.

NuBiyota is a microbiome therapeutics company focused on the development of novel microbiota-based drugs to restore crucial gut equilibrium. An imbalance in this crucial ecosystem is associated with infections, chronic disease and even neurological dysfunction. NuBiyota is developing a new class of microbiome therapeutics, with multi-strain microbiota candidates for effective microbiota diversity restoration to suppress flares or promote remission in numerous indications

Prime Discoveries develops rapid, novel diagnostics for emerging pathogen infections with a focus on cost effective, massively scalable and easily automatable assays. Prime leverages multiple patented advanced technologies in microbial diagnostics including RT-LAMP, Rapid PCR, and mNGS (Next generation sequencing) to enable samples to result in under 1 hour with minimal lab infrastructure and technical expertise. Prime's products are best in class for Covid, Influenza, Sexually Transmitted Infections and new drug resistant microbes. All of Prime's assays are locally developed in the United States and can serve millions of people. Founded in NYC in 2017, Prime's scientists have extensive backgrounds in microbiology, computational biology, lab automation and AI from Genentech, Cooper Genomics, Recombine, Phosphorus, and NYU. Prime is advised by leading experts in the fields of genomics and public health including Dr. George Church and Esther Dyson. Prime is supported by academic institutions, venture capital firms and angel investors including New York University, Charles Zegar, BoxGroup, Akron Fusion Ventures, Beresford Ventures, Cannonball Capital, Liquid 2 Ventures, Francois Nader (Moderna, Acceleron, Shire), Unshackled Ventures, Doberman Forward, and others.

Profacgen offers a full range of biopharmaceutical development and bio-manufacturing services that cover strategic consultancy,process development, cGMP manufacturing, and analytical development.

PsychoGenics is a preclinical CRO with expertise in CNS and orphan disorders. Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments for severely disabling CNS and orphan disorders, and reduce the attrition rate in clinical development. We are known for our cutting-edge translational approach to research, our customized solutions, the breadth and quality of our work, as well as for our ability to identify statistically relevant phenotypic changes that help our clients quantify the efficacy of their treatments before they move into the clinic. With an extensive portfolio of highly predictive disease models and unparalleled experience performing studies for biopharmaceutical companies of all sizes, we enable clients to deliver much needed superior clinical candidates to patients. Our capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. We offer a variety of validated mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, autism spectrum disorders, psychosis and schizophrenia, spinal muscular atrophy, muscular dystrophy and a broad array of pain models.

Founded in 2017, Redesign Science is a platform biotech working at the interface of physics-based molecular simulation and deep learning to create generative AI for drug discovery. We deploy our platform technology to develop first-in-class Protein Interaction Modulators against validated targets known to drive progression of multiple oncogenic and inflammatory diseases.

Rumi Scientific is a research-driven company focused on the discovery of drugs and innovative treatments for human genetic diseases. The company's mission is to fast-track the early stage of drug discovery using predictive models of the human brain for therapeutic success.

Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. Its segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; Thermo Fisher Scientific to extend the use of cryo-EM in connection within silico compound screening to accelerate drug discovery; and Bristol Myers Squibb Company to discover, develop, and commercialize therapeutics in multiple disease areas. The company was founded in 1990 and is based in New York.

SolveBio is a data analytics company that specializes in advanced precision medicine for biopharma customers, aiming to lower trial risk, develop more effective therapeutics, and accelerate clinical development timelines.

Headquartered in Rochester, NY, VisualDx’s team of physicians, educators, and computer scientists have developed an award-winning web-based clinical decision support system to enhance clinical decision-making and improve patient care. It has become the tool of choice for front line health care workers who are looking for a visual, curated, peer-reviewed approach to medicine.

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.